Why the study?
There is a lack of consensus among national guidelines regarding the choice between DOACs and LMWH, agent selection, dosing strategy, and duration of anticoagulation for cancer-associated venous thromboembolism.
What is the optimal anticoagulant treatment (DOACs vs LMWH) for patients with cancer-associated VTE?
What is the optimal anticoagulant treatment (DOACs vs LMWH) for patients with cancer-associated VTE?
This systematic review highlights ongoing controversies and lack of consensus in national guidelines regarding the optimal anticoagulant choice, dosing, and duration for cancer-associated VTE.
Real-world data may guide individualized DOAC selection in cancer-associated VTE; leaves open optimal dosing, duration, and high-risk subgroups.
Cancer-associated venous thromboembolism (VTE) is a common complication of malignancy. Patients with cancer exhibit risk factors for both recurrent VTE and major or minor bleeding. Direct oral anticoagulants (DOACs) are an attractive treatment option; however, there is a lack of consensus among national guidelines for choice between DOACs and LMWH, agent selection, dosing strategy, and duration of anticoagulation. Characteristics of the thrombotic event, the malignancy, the patient, and the anticoagulant must be considered. A systematic search of online databases was performed to identify literature on the management of cancer-associated VTE. Multiple controversies remain surrounding the optimal treatment of cancer-associated VTE.
No takes yet. Share an insight, caveat, or question.
Nachar et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: